Communiqués de presse Archive - Page 17 of 22 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Receives €5.2 M in Public Funding

OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 of FR104

OSE Immunotherapeutics to Present at SITC Annual Meeting And Additional Summits

OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT

OSE Immunotherapeutics Presents OSE-230

OSE Immunotherapeutics Announces Publication for Selective Antibody Antagonist BI765063

OSE Immunotherapeutics Receives European Patent Notice of Allowance for FR104

OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC

OSE Immunotherapeutics Reports First Half 2020 Results

OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Précédent
1
…
14
15
16
17
18
19
20
…
22
Suivant